Immune Thrombocytopenia clinical trials

Explore recruiting immune thrombocytopenia clinical trials.

Recruiting immune thrombocytopenia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Immune Thrombocytopenia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1/2, Dose-finding Study Investigating the Safety and Efficacy of Pirtobrutinib in Adults with Immune Thrombocytopenia

France, Italy, Denmark, Spain, Poland, Norway

Phase I and Phase II (Integrated)- Other EU CTIS Study details

ARGX-113-1803: A Phase 3, Multicenter, Open-label, Long-term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia

Italy, Czechia, Poland, Hungary

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of Rilzabrutinib (PRN1008), an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenia

Czechia, Netherlands, Bulgaria

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Complex immunomodulatory therapy for patients with immune thrombocytopenia (T-MEM)

Czechia

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants with Chronic Primary Immune Thrombocytopenia

Poland, Spain, Bulgaria, Italy, Netherlands, Croatia +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

ARGX-113-2409: A Multicenter, Randomized, Double-blinded, Parallel-Arm, Placebo- Controlled, Pharmacokinetic and Pharmacodynamic Study Followed by an Open-Label Arm to Evaluate Efgartigimod IV in Pediatric Participants from 12 Years to Less Than 18 Years of Age with Chronic ITP

Lithuania, Romania, Hungary, France, Italy, Spain +2 more

Phase II and Phase III (Integrated) EU CTIS Study details

Immune Thrombocytopenia trials by city

Immune Thrombocytopenia in Toronto Immune Thrombocytopenia in Vancouver Immune Thrombocytopenia in Montreal Immune Thrombocytopenia in Calgary Immune Thrombocytopenia in Edmonton Immune Thrombocytopenia in Ottawa Immune Thrombocytopenia in Winnipeg Immune Thrombocytopenia in Quebec City Immune Thrombocytopenia in Hamilton Immune Thrombocytopenia in Kitchener Immune Thrombocytopenia in London Immune Thrombocytopenia in Halifax Immune Thrombocytopenia in New York Immune Thrombocytopenia in Los Angeles Immune Thrombocytopenia in Chicago Immune Thrombocytopenia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease